Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Renhe Pharmacy Co., Ltd. (000650.SZ)
Nanchang, CN
Renhe Pharmacy Co., Ltd. is a pharmaceutical enterprise engaged in the manufacturing and distribution of a wide array of products. Its diverse portfolio includes both traditional Chinese and modern Western medicines, their essential raw materials, and various health and wellness items. These offerings are presented in numerous forms, such as oral solid preparations (e.g., tablets, capsules), liquid medications, large and small volume injectable solutions, topical treatments like lotions, liniments, and ointments, as well as suppositories and other health-related product formats. The company, which was established in 1996, maintains its corporate headquarters in Nanchang, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.10% | -1.29% | -6.14% | -11.13% | -10.39% | -5.31% | -3.08% | -19.91% | -54.08% | -26.00% | +328.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-13.2% Q1'26: +14.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-20.0% Q1'26: -15.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+20.9% ★ Q1'26: +11.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.8% ★ Q1'26: +21.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+15.9% ★ Q1'26: +22.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
4.07B
est: 5.28B (-22.8%)
|
3.54B
est: 5.76B (-38.6%)
|
3.82B
3.82B – 3.82B
-33.7% YoY
|
4.05B
4.05B – 4.05B
+6.0% YoY
|
4.29B
4.29B – 4.29B
+6.0% YoY
|
| EBITDA |
787.04M
est: 1.08B (-27.2%)
|
780.83M
est: 1.18B (-33.9%)
|
782.37M
782.37M – 782.37M
-33.7% YoY
|
829.48M
829.48M – 829.48M
+6.0% YoY
|
879.47M
879.47M – 879.47M
+6.0% YoY
|
| EBIT |
671.27M
est: 948.07M (-29.2%)
|
664.98M
est: 1.03B (-35.7%)
|
685.74M
685.74M – 685.74M
-33.7% YoY
|
727.03M
727.03M – 727.03M
+6.0% YoY
|
770.85M
770.85M – 770.85M
+6.0% YoY
|
| Net Income |
481.91M
est: 747.65M (-35.5%)
|
393.21M
est: 844.57M (-53.4%)
|
401.52M
401.52M – 401.52M
-52.5% YoY
|
443.05M
443.05M – 443.05M
+10.3% YoY
|
484.59M
484.59M – 484.59M
+9.4% YoY
|
| SGA |
745.42M
est: 758.17M (-1.7%)
|
127.45M
est: 827.53M (-84.6%)
|
548.38M
548.38M – 548.38M
-33.7% YoY
|
581.41M
581.41M – 581.41M
+6.0% YoY
|
616.44M
616.44M – 616.44M
+6.0% YoY
|
| EPS |
0.35
est: 0.54 (-35.5%)
|
0.28
est: 0.61 (-54.1%)
|
0.29
0.29 – 0.29
-52.5% YoY
|
0.32
0.32 – 0.32
+10.3% YoY
|
0.35
0.35 – 0.35
+9.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 45.7K | 0.65% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 59.2K | 0.46% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 284.4K | 0.06% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 160.3K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 113.5K | 0.29% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.2K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 20.7K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.02M | 0.06% |
| 9 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 3.3K | 0.44% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 58.0K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Jiang | Secretary of the Board & Non-Independent Director | — | male |
| Guofeng Chen | Deputy General Manager | — | male |
| Lingyun Zhu | Accounting Supervisor | — | — |
| Qiu Lin Peng | Chief Financial Officer & Non-Independent Director | — | male |
| Wujun Huang | GM & Director | — | male |
| Zi Qiang Zhang | Deputy GM & Employee Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000650.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
